Cyclooxygenase-2 inhibitors in postoperative pain management;Postoperatif aǧri tedavisinde siklooksijenaz-2 inhibitörleri

Agri

Volumn 16, Issue 3, 2004, Pages 7-16

  Güneş, Yasemin ^a   Işik, Geylan ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Cyclooxygenase inhibitors; Nonsteroidal antiinflammatory drugs; Postoperative pain

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; ROFECOXIB; VALDECOXIB;

ANALGESIC ACTIVITY; CONFERENCE PAPER; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; HEMOSTASIS; HUMAN; KIDNEY INJURY; POSTOPERATIVE PAIN; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTE DYSFUNCTION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; HUMANS; LACTONES; PAIN, POSTOPERATIVE; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 4544268615     PISSN: 13000012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Ancian P., Lambeau G., Mattei M. G., Lazdunski M.: The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J Biol Chem. 1995; 270: 8963-8970.
2. Barden J., Edwards J. E., McQuay H. J., Moore R. A.: Single-dose rofecoxib for acute postoperative pain in adults: a quantitative systematic review. BMC Anesthesiology 2002; 2: 4 (1-6).
3. Barton S. F., Langeland F. F., Snabes M. C., LeComte, D., Kuss M. E., Dhadda S. S., Hubbard R. C.: Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology. 2002; 97: 306-314.
4. Beiche F., Brune K., Geisslinger G., Goppelt-Struebe M.: Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inflamm Res 1998; 47: 482-487.
5. Beiche F., Scheuerer S., Brune K., Geisslinger G., Goppelt-Struebe M.: Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996; 390: 165-169.
6. Bekker A., Cooper P. R., Frempong-Boadu A., Babu R., Errico T., Lebovits A.: Evaluation of preoperative administration of the cyclooxygenase-2 inhibitor rofecoxib for the treatment of postoperative pain after lumbar disc surgery. Neurosurgery 2002; 50: 1053-1057.
7. Bhopatkar S.Y., Reuben S.S., Joshi W., Maciolek H.: Preemptive analgesic effects of rofecoxib for ambulatory arthroscopic knee surgery 2001; 95: A34.
8. Bley K. R., Hunter J. C., Eglen R. M., Smith J. A.: The role of IP prostanoid receptors in inflammatory pain. Trends Pharmacol Sci 1998; 19: 141-147.
9. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M. B., Hawkey C. J., Hochberg M. C., Kvien T. K., Schnitzer T. J.; VICOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
10. Buvanendran A., Elmofty D., Lubenow T. J., Kroin J. S., Turnan K. J.: Perioperative administration of selective cyclooxygenase-2 (COX-2) inhibitor reduces postoperative epidural drug consumption after total knee arthroplasty (TKA) (abstract). ASA 2002; 96: A943.
11. Buvanendran A., Elmofty D., Moric M., Kroin J. S., Tuman K. J.: Rofecoxib reduces postoperative opioid consumption and improves range of motion after total knee arthroplasty (TKA) (abstract). ASA 2003; A-1116.
12. Camu F., Beecher T., Recker D. P., Verburg K. M.: Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002; 9: 43-51.
13. Celik J. B., Tuncer S., Reisli R., Sarkilar G., Celik C., Akyurek C.: A comparative study of the effect of rofecoxib (a COX 2 inhibitor) and naproxen sodium on analgesic requirements after abdominal hysterectomy. Arch Gynecol Obstet 2003; 268: 297-300.
14. Cho J., Cooke C. E., Proveaux W.: Retrospective review of the effect of COX-2 inhibitors on blood pressure change. American Journal of Therapeutics 2003; 10: 311-317.
15. Depre M., Ehrich E., Van Hecken A., De Lepeleire I., Dallob A., Wong P., Porras A., Gertz B. J., De Schepper P. J.: Pharmacokinetics, COX-2 specifity, and tolerability of supratherapeuthic doses of rofecoxib in humans. Eur J Pharmacol 2000; 56: 167-174.
16. Dimar J. R. 2nd, Ante W. A., Zhang Y. P., Glassman S. D.: The effects of nonsteroidal anti-inflammatory drugs on posterior spinal fusions in the rat. Spine 1996; 21: 1870-1876.
17. Dionne R.: COX-2 inhibitors: better than ibubrufen for dental pain? Compend Contin Educ Dent 1999; 20: 518-520.
18. Ehrich E. W., Schnitzer T. J., McIlwain H., Levy R., Wolfe F., Weisman M., Zeng Q., Morrison B., Bolognese J., Seidenberg B., Gertz B. J.: Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. J Rheumatol 1999; 26: 2438-2447.
19. Evans A. R., Junger H., Southall M. D., Nicol G. D., Sorkin L. S., Broome J.T., Bailey T.W., Vasko M.R.: Isoprostanes, novel eicosanoids that produce nociception and sensitize rat sensory neurons. J Pharmacol Exp Ther 2000; 293: 912-920.
20. Filos K. S., Lehmann K. A.: Current concept and practice in postoperative pain management: need for a change? Eur Surg Res1999; 31: 997-1007.
21. FitzGerald G. A., Patrono C.: The coxibs, selective inhibitors of cyclooxygenase-2. N Eng J Med 2001; 345: 433-442.
22. FitzGerald G. A.: Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002; 89 (6A): 26D-32D.
23. Funk C. D., Funk L. B., Kennedy M. E., Pong A. S., Fitzgerald G. A.: Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991; 5: 2304-2312.
24. Gajraj N. M.: Cyclooxygenase-2 inhibitors. Anest Analg 2003; 96: 1720-1738.
25. Gimbel J. S., Brugger A., Zhao W., Verburg K. M., Geis G. S.: Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001; 23 (2): 228-241.
26. Gilron I., Milne B., Hong M.: Cyclooxygenase-2 inhibitors in postoperative pain management: current evidence and future directions. Anesthesiology 2003, 99: 1198-1208.
27. Glassman S. D., Rose S. M., Dimar J. R., Puno R. M., Campbell M. J., Johnson J. R.: The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 1998; 23: 834-838.
28. Grass J. A.: Assessment of ketorolac as an adjuvant to fentanyl patient-controlled epidural analgesia after radical retropubic prostatectomy. Anesthesiology 1993; 78: 642-648.
29. Greenberg H. E., Gottesdiener K., Huntington M., Wong P., Larson P., Wildonger L., Gillen L., Dorval E., Waldman S. A.: A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000; 40: 1509-1515.
30. Hla T., Neilson K.: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 1992; 89: 7384-7388.
31. Ho M. L., Chang J. K., Wang G. J.: Antiinflammatory drug effects on bone repair and remodeling in rabbits. Clin Orthop 1995; 313: 270-278.
32. Huang J. J., Taguchi A., Hsu H., Andriole G. L. Jr, Kurz A.: Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial. J Clin Anesth 2001; 13: 94-97.
33. Issioui T., Klein K. W., White P. F., Hu J., Skrivanek G. D.: Analgesic efficacy of rofecoxib alone or in combination with acetominophen in the ambulatory setting. (abstract). ASA 2001; 95: A35.
34. Issioui T., Klein K. W., White P. F., Watcha M. F., Coloma M., Skrivanek G. D., Jones S. B., Thornton K. C., Marple B. F.: The efficacy of premedication with celecoxib and acetaminophen in preventing pain after otolaryngologic surgery. Anesth Analg 2002; 94: 1188-1193.
35. Joshi W., Connelly N. R., Reuben S. S., Wolckenhaar M., Thakkar N.: An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg 2003; 97: 35-38.
36. Katz W. A.: Cyclooxygenase-2 selective inhibitors in the management of acute and perioperative pain. Cleve Clin J Med 2002; 69 (Suppl) 1: S165-75.
37. Kharasch E.: Perioperative COX-2 inhibitors: knowledge and challenges. Anesth Analg 2004; 98: 1-3.
38. Laine L.: Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996; 6: 489-504.
39. Leese P. T., Recker D. P., Kent J. D.: The COX 2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol 2003: 43: 504-513.
40. Lerea L. S., Carlson N. G., Simonato M., Morrow J. D., Roberts J. L., McNamara J. O.: Prostaglandin F2 alpha is required for NMDA receptor-mediated induction of c-fos mRNA in dentate gyrus neurons. Neurosci 1997; 17: 117-124.
41. Long J., Lewis S., Kuklo T., Zhu Y., Riew K. D.: The effect of cyclooxygenase-2 inhibitors on spinal fusion. J Bone Joint Surg Am 2002; 84-A: 1763-1768.
42. Malmstrom K., Daniels S., Kotey P., Seidenberg B. C., Desjardins P. J.; Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator- controlled clinical trial. Clin Ther 1999; 21: 1653-1663.
43. Matsumura K., Watanabe Y., Onoe H., Watanabe Y.: Prostacyclin receptor in the brain and central terminals of the primary sensory neurons: an autoradiographic study using a stable prostacyclin analogue [3H] iloprost. Neuroscience 1995; 65: 493-503.
44. McCrory C. R., Lindahl S. G.: Cyclooxygenase inhibition for postoperative analgesia. Anesth Analg 2002; 95: 169-176.
45. Minami T., Uda R., Horiguchi S., Ito S., Hyodo M., Hayaishi O.: Allodynia evoked by intrathecal administration of prostaglandin E2 to conscious mice. Pain 1994; 57: 217-223.
46. Morrison B. W., Christensen S., Yuan W., Brown J., Amlani S., Seidenberg B.: Analgesia efficacy cyclooxygenase-2 spesific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999; 21: 943-952.
47. Morrison B. W., Fricke J., Brown J., Yuan W., Kotey P., Mehlisch D.: The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials. J Am Dent Assoc 2000; 131: 1729-1737.
48. Mukherjee D., Nissen S. E., Topol E. J.: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
49. Okamoto T., Hino O.: Expression of cyclooxygenase-1 and -2 mRNA in rat tissues: tissue-specific difference in the expression of the basal level of mRNA. Int J Mol Med 2000; 6: 455-457.
50. Pitcher G. M., Henry J. L.: Mediation and modulation by eicosanoids of responses of spinal dorsal horn neurons to glutamate and substance P receptor agonists: results with indomethacin in the rat in vivo. Neuroscience 1999; 93: 1109-1121.
51. Rainsford K. D.: Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 1999; 107 (6A): 27S-35S.
52. Ray W. A., Stein C. M., Daugherty J. R., Hall K., Arbogast P. G., Griffin M. R.: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
53. Reicin A., Brown J., Jove M., deAndrade J. R., Bourne M., Krupa D., Walters D., Seidenberg B.: Efficacy of single dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. Am J Orthop 2001; 30: 40-48.
54. Reuben S. S., Connelly N.R.: Postoperative analgesic effect of celecoxib or rofecoxib after spinal surgery. Anesth Analg 2000; 91: 1221-1225.
55. Reuben S. S., Bhopatkar S., Maciolek H., Joshi W., Sklar J.: The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg 2002; 94: 55-59.
56. Reuben S., Fingeroth R., Krushell R., Maciolek H.: Evaluation of the safety anf efficacy of the perioperative administration of rofecoxib for total knee arthoplasty. J Arthoplasty 2002; 17: 26-31.
57. Robinson C. M., Christie J., Malcolm-Smith N.: Nonsteroidal antiinflamatory drugs, perioperative blood loss, and transfusion requirements in elective hip arthoplasty. J Arthoplasty 1993; 8: 607-610.
58. Schafer A. I.: Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. Clin Pharmacol 1995; 35: 209-219.
59. Schwartz J. I., Agrawal N. G., Wong P. H., Bachmann K. A., Porras A. G., Miller J. L., Ebel D. L., Sack M. R., Holmes G. B., Redfern J.S., Gertz B.J.: Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. J Clin Pharmacol 2001; 41: 1120-1130.
60. Seeberg P. H.: The TIPPS/TINS lecture: the molecular biology of the mammalian glutamate receptor changes. Trends Pharmacol Sci 1993; 14: 297-303.
61. Shen Q., Sinatra R., Luther M., Halaszynski T.: Preoperative rofecoxib 25 mg and 50 mg: effects on post-surgical morphine consumption and effort dependent pain. (abstract). ASA 2001; 95: A-961.
62. Simon L. S., Weaver A. L., Graham D. Y., Kivitz A. J., Lipsky P. E., Hubbard R. C., Isakson P. C., Verburg K. M., Yu S. S., Zhao W. W., Geis G. S.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-1928.
63. Sinatra R. S.: Role of COX-2 inhibitors in the evolution of acute pain management. Journal of Pain and Symptom Management 2002; 24: No. 1S.
64. Sinatra R. S., Shen Q. J., Halaszynski T., Luther M. A., Shaheen Y.: Preoperative rofecoxib oral suspension as all analgesic adjunt following lower abdominal surgery: effects on effort-dependent pain and pulmonary function. Anesth Analg 2004; 98: 135-140.
65. Smith W.L.: Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-191.
66. Stephens J., Laskin B., Pashos C., Pena B., Wong J.: The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology 2003; 42: 40-52.
67. Weir M. R., Sperling R. S., Reicin A., Gertz B. J.: Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program. Am Heart J 2003; 146: 591-604.
68. Weaver A. L.: Rofecoxib: clinical pharmacology and clinical experience. Clin Ther 2001; 23: 1323-1338.
69. Whelton A., White W. B., Bello A. E., Puma J. A., Fort J. G.; SUCCESS-VII Investigators: Effect of celecoxib and rofecoxib on blood pressure and edema in patients ≥ 65 years of age with systemic hypertension and osteoartritis. Am J Cardiol 2002; 90: 959-963.
70. Widlansky M. E., Price D. T., Gokce N., Eberhardt R. T., Duffy S. J., Holbrook M., Maxwell C., Palmisano J., Keaney J. F. Jr., Morrow J. D., Vita J. A.: Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003; 42: 310-315.
71. Willingale H. L., Gardiner N. J., McLymont N., Giblett S., Grubb B. D.: Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br J Pharmacol. 1997; 122: 1593-1604.
72. Woolf C. J., Chong M. S.: Preemtive analgesia: threating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993; 77: 362-379.
73. Zhang X., Morham S.G., Langenbach R., Young D.A., Xing L., Boyce B.F., Puzas E.J., Rosier R.N., O'Keefe R.J., Schwarz E.M.: Evidence for a direct role of cyclo-oxygenase-2 in implant wear debris-induced osteolysis. J Bone Miner Res 2001; 16: 660-670.
74. Zhao Z., Chen S.R., Eisenach J.C., Busija D.W., Pan H.L.: Spinal cyclooxygenase-2 is involved in development of allodynia after nerve injury in rats. Neuroscience 2000; 97: 743-748.